RT Journal Article
SR Electronic
T1 Evaluating the impact of international airline suspensions on COVID-19 direct importation risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.20.20025882
DO 10.1101/2020.02.20.20025882
A1 Aniruddha Adiga
A1 Srini Venkatramanan
A1 Akhil Peddireddy
A1 Alex Telionis
A1 Allan Dickerman
A1 Amanda Wilson
A1 Andrei Bura
A1 Andrew Warren
A1 Anil Vullikanti
A1 Brian D Klahn
A1 Chunhong Mao
A1 Dawen Xie
A1 Dustin Machi
A1 Erin Raymond
A1 Fanchao Meng
A1 Golda Barrow
A1 Hannah Baek
A1 Henning Mortveit
A1 James Schlitt
A1 Jiangzhuo Chen
A1 Jim Walke
A1 Joshua Goldstein
A1 Mark Orr
A1 Przemyslaw Porebski
A1 Richard Beckman
A1 Ron Kenyon
A1 Samarth Swarup
A1 Stefan Hoops
A1 Stephen Eubank
A1 Bryan Lewis
A1 Madhav Marathe
A1 Chris Barrett
YR 2020
UL http://medrxiv.org/content/early/2020/02/23/2020.02.20.20025882.abstract
AB Global airline networks play a key role in the global importation of emerging infectious diseases. Detailed information on air traffic between international airports has been demonstrated to be useful in retrospectively validating and prospectively predicting case emergence in other countries. In this paper, we use a well-established metric known as effective distance on the global air traffic data from IATA to predict COVID-19 times of arrival (ToA) for different countries as a consequence of direct importation from China. Using this model trained on official first reports from WHO, we provide estimated ToA for all other countries. By combining effective distance with a measure for the country’s vulnerability (Infectious Disease Vulnerability Index (IDVI)), we propose a metric to rank vulnerable countries at immediate risk of case emergence. We then incorporate data on airline suspensions to recompute the effective distance and assess the effect of such cancellations in delaying the estimated arrival time for all other countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to thank members of the Network Systems Science and Advanced Computing (NSSAC) Division for interesting discussion and suggestions related to epidemic science and machine learning. This work was partially supported by National Institutes of Health (NIH) Grant 1R01GM109718, NSF BIG DATA Grant IIS-1633028, NSF DIBBS Grant ACI-1443054, DTRA subcontract/ARA S-D00189-15-TO-01-UVA, NSF Grant No.: OAC-1916805 and US Centers for Disease Control and Prevention 75D30119C05935.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data except from proprietary sources used in the analysis are made available as Supplemental material. https://doi.org/10.18130/V3/Z6524P